| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $168.6M | +139.6% |
| SG&A Expense | $23.8M | +66.6% |
| Operating Income | -$192.4M | -127.3% |
| Net Income | -$177.8M | -147.3% |
| EPS (Basic) | -$3.66 | -83.9% |
| EPS (Diluted) | -$3.66 | -83.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $114.1M | +131.4% |
| Current Assets | $205.4M | -17.6% |
| Total Assets | $205.9M | -18.2% |
| Current Liabilities | $14.6M | +39.7% |
| Stockholders' Equity | $191.3M | -20.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$166.3M | -104.9% |
| Investing Cash Flow | $115.0M | +171.6% |
| Financing Cash Flow | $116.1M | -42.9% |